Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Abstract As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT ha...

Description complète

Détails bibliographiques

Auteurs principaux:	Peng Zhang, Xinyuan Liu, Zhuoyu Gu, Zhongxing Jiang, Song Zhao, Yongping Song, Jifeng Yu
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2024-01-01
Collection:	Biomarker Research
Sujets:	TIGIT Target immunotherapy Immune checkpoint pathway cancer immunotherapy Clinical trial
Accès en ligne:	https://doi.org/10.1186/s40364-023-00543-z
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!